Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: A phase 2 trial

Kent A. Robertson, Grzegorz Nalepa, Feng Chun Yang, Daniel C. Bowers, Chang Y. Ho, Gary D. Hutchins, James M. Croop, Terry A. Vik, Scott C. Denne, Luis F. Parada, Cynthia M. Hingtgen, Laurence E. Walsh, Menggang Yu, Kamnesh R. Pradhan, Mary K. Edwards-Brown, Mervyn D. Cohen, James W. Fletcher, Jeffrey B. Travers, Karl W. Staser, Melissa W. LeeMarcie R. Sherman, Cynthia J. Davis, Lucy C. Miller, David A. Ingram, D. Wade Clapp

Research output: Contribution to journalArticlepeer-review

187 Scopus citations

Fingerprint

Dive into the research topics of 'Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: A phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences